abstract |
The present invention provides compositions and methods for treating leukemias, such as acute myeloid leukemia (AML) and B cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific for CD123, a vector comprising the receptor, and a recombinant T cell comprising the CD123 CAR. The invention also encompasses methods of administering genetically modified T cells that express a CAR comprising a CD123 binding domain. The invention also encompasses methods for bone marrow clearance that require treatment of bone marrow reconditioning or transplantation. |